# Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

> **NCT00698685** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 14 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Hodgkin's Disease
- Hematologic Neoplasms
- Multiple Myeloma
- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Pentostatin
- **BIOLOGICAL:** Alemtuzumab
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00698685
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01-23
- **Primary completion:** 2009-04-13
- **Final completion:** 2011-04-26
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Pentostatin/alemtuzumab regimen had greater risk of graft failure.
- **Last updated:** 2017-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698685, "Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00698685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*